Supplementary Figure S4 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy

Katsushige Kawase; Shusuke Kawashima; Tatsuya Nishi; Takashi Inozume; Takao Morinaga; Masahito Kawazu; Toyoyuki Hanazawa; Yosuke Togashi

doi:10.1158/2326-6066.30255052

October 1, 2025

Supplementary Figure S4 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study identifies the PI3K/Akt signaling pathway as a key regulator of CD155 expression in cancer contexts.
Higher CD155 expression correlates with resistance to cancer immunotherapy, indicating potential therapeutic targets.
Assessment of various DYRK1A inhibitors highlights their effects on CD155 regulation and potential to enhance immunotherapy.
Further exploration of the PI3K/Akt pathway may lead to new strategies to overcome immunotherapy resistance.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

This analysis reveals how the PI3K/Akt signaling pathway influences CD155 expression in cancer, highlighting implications for immunotherapy strategies.

Abstract

Additional data on other inhibitors of DYRK1A

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kawase et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21abd https://doi.org/10.1158/2326-6066.30255052

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S4 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading